SGLT-2 Inhibitors in Heart Failure: Putting the Evidence Into Practice

Published: 27 August 2021

  • Views:

    Views Icon 8401
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Andrew Coats (Monash University, Australia and University of Warwick, UK) and Prof Giuseppe Rosano (St George's, University of London, UK) discuss the implications for treatment strategies.


This three-part series provides comprehensive update on some of the most important developments in HFrEF management including addressing key considerations of where SGLT-2 inhibitors fit into the new guidelines for HFrEF, when and how to initiate SGLT-2 inhibitors, and making evidence-based choices in the selection of SGLT-2 inhibitor.

This programme is supported by an unrestricted educational grant from AstraZeneca

Learning Objectives

  • Recall the latest recommendations and levels of evidence supporting the use of SGLT-2 inhibitors in heart failure (HF)
  • Consider the impact of delaying the adoption of all guideline-directed foundational therapies in existing HF
  • Make an evidence-based choice when selecting an SGLT-2 inhibitor in HF

Target Audience

  • Heart failure specialists
  • Cardiologists
  • Referring physicians
  • Allied health professionals

More from this programme

Part 1

Where Do SGLT-2 Inhibitors Fit Into the New Guidelines for HFrEF?

Part 2

When and How to Initiate SGLT-2 Inhibitors in HFrEF

Part 3

Choosing an SGLT-2 Inhibitor – Making an Evidence-based Choice

Faculty Biographies

Andrew JS Coats

Andrew JS Coats

Professor of Cardiology and Scientific Director

Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.

Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.

He is an…

View full profile
Giuseppe Rosano

Giuseppe Rosano

Consultant Cardiologist and Professor of Cardiology (Hon)

Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.

His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases. Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian Drug Agency. He is the President-Elect of the Heart Failure Association Board (HFA), and Chairman of the Education Committee of the HFA. Prof Rosano is on the editorial board for European Journal of Heart Failure, European Heart Journal CV Pharmacotherapy, Cardiac Failure Reviews and Cardiovascular Diabetology. He has authored more than 500 peer…

View full profile